In colorectal cancer models, combined treatment with gallic acid and anti-PD-1 antibody reduces Treg cell function, boosts CD8+ T cell IFN-γ production, and restricts tumor growth, suggesting a potent therapeutic strategy to improve ICB outcomes by inducing T-helper-1-like Treg cells [106]. The gene discussed is CD8A; the disease is colorectal cancer.